North American Management Corp lifted its stake in Pfizer Inc. (NYSE:PFE) by 18.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 177,997 shares of the biopharmaceutical company’s stock after purchasing an additional 27,109 shares during the period. North American Management Corp’s holdings in Pfizer were worth $6,447,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of PFE. Augustine Asset Management Inc. lifted its position in Pfizer by 70.6% during the 4th quarter. Augustine Asset Management Inc. now owns 32,275 shares of the biopharmaceutical company’s stock valued at $1,169,000 after acquiring an additional 13,351 shares during the period. Oakworth Capital Inc. lifted its position in Pfizer by 1.3% during the 4th quarter. Oakworth Capital Inc. now owns 207,024 shares of the biopharmaceutical company’s stock valued at $7,504,000 after acquiring an additional 2,754 shares during the period. Steward Partners Investment Advisory LLC lifted its position in Pfizer by 12.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 226,657 shares of the biopharmaceutical company’s stock valued at $8,209,000 after acquiring an additional 25,979 shares during the period. Plancorp LLC lifted its position in Pfizer by 6.1% during the 4th quarter. Plancorp LLC now owns 34,273 shares of the biopharmaceutical company’s stock valued at $1,240,000 after acquiring an additional 1,961 shares during the period. Finally, V Wealth Management LLC purchased a new position in Pfizer during the 4th quarter valued at about $214,000. 71.16% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Rady A. Johnson sold 27,323 shares of Pfizer stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $36.55, for a total value of $998,655.65. Following the completion of the sale, the executive vice president now directly owns 70,332 shares in the company, valued at $2,570,634.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Charles H. Hill sold 42,393 shares of Pfizer stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock valued at $9,064,785 over the last quarter. Company insiders own 0.06% of the company’s stock.
A number of brokerages recently issued reports on PFE. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research report on Tuesday, January 2nd. Jefferies Group set a $39.00 price target on shares of Pfizer and gave the company a “hold” rating in a research report on Monday, February 26th. Morgan Stanley set a $41.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, January 8th. Finally, Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective for the company in a research note on Monday, January 8th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $39.40.
Shares of Pfizer Inc. (NYSE:PFE) opened at $35.60 on Friday. Pfizer Inc. has a 12 month low of $31.67 and a 12 month high of $39.43. The company has a market cap of $215,910.41, a P/E ratio of 13.69, a PEG ratio of 1.82 and a beta of 0.91. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The firm had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same period in the previous year, the business posted $0.47 earnings per share. The business’s revenue for the quarter was up .6% on a year-over-year basis. research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer announced that its Board of Directors has approved a share repurchase program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/23/pfizer-inc-pfe-shares-bought-by-north-american-management-corp.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.